Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.49 |
| ▸ | ITGAV | P06756 | 19/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809549 | 0.85 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7919632 | 0.84 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7856513 | 0.79 | ITGB3 (0.45) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6798729 | 0.73 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL8444235 | 0.73 | ITGB3 (0.65) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2833888 | 0.72 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2834278 | 0.72 | ITGB3 (0.63) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL8524582 | 0.72 | ROCK2 (0.40) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL2833606 | 0.72 | ITGB3 (0.61) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL13109233 | 0.71 | ITGB3 (0.67) | ITGB3ITGAVITGB6ITGA2BITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140193-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |